mycancerdrugs - List of cancer drugs
The following drugs are targeted cancer drugs that are covered by your WPA policy under the therapeutic indications detailed below where these are not available to you as an NHS patient and are regularly updated on our website. This information is correct as of the 27th March 2008.
| Trade name - common name | The therapeutic indication(s) licensed by the EMEA | References | Indicative Costs* |
|---|---|---|---|
| Alimta® - Pemetrexed Disodium | Alimta in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Note 1 Alimta is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer after prior chemotherapy. Note 1 |
www.emea.europa.eu/ humandocs/Humans/ EPAR/alimta/alimta.htm www.cancerbackup.org.uk/ Treatments/Chemotherapy/ Individualdrugs/Pemetrexed |
£1,600 per month |
| Avastin® - Bevacizumab | Avastin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum. Avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer (MBC). Avastin, in addition to platinum-based chemotherapy, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology. Avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and/or metastatic renal cell cancer (MRCC). |
www.emea.europa.eu/ humandocs/Humans/ EPAR/avastin/avastin.htm www.cancerbackup.org.uk/ Treatments/Biologicaltherapies/ Monoclonalantibodies/Bevacizumab |
Bowel-£2,800 MBC-£2,800 NSCLC-£1,400-£2,800 MRCC - £2,800 per month |
| Erbitux® - Cetuximab | Erbitux in combination with irinotecan is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Erbitux in combination with radiation therapy is indicated for the treatment of patients with locally advanced squamous cell cancer of the head and neck. |
www.emea.europa.eu/ humandocs/Humans/ EPAR/erbitux/erbitux.htm www.cancerbackup.org.uk/ Treatments/Biologicaltherapies/ Monoclonalantibodies/Cetuximab |
£2,730 per month |
| MabCampath® - Alemtuzumab | MacCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate. | www.emea.europa.eu/ humandocs/Humans/ EPAR/mabcampath/ mabcampath.htm www.cancerbackup.org.uk/ Treatments/Biologicaltherapies/ Monoclonalantibodies/Alemtuzumab |
£9,894 per month |
| Nexavar® - Sorafenib | Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. |
www.emea.europa.eu/ humandocs/Humans/ EPAR/nexavar/nexavar.htm www.cancerbackup.org.uk/ QAs/14074737 |
£2,505 per month |
| Sutent® - Sunitinib | Gastrointestinal Stromal Tumour (GIST) Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance. Metastatic Renal Cell Carcinoma (MRCC) Sutent is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (MRCC). |
www.emea.europa.eu/ humandocs/Humans/ EPAR/sutent/sutent.htm www.cancerbackup.org.uk/ QAs/21213104 |
£3,363 per month |
| Tarceva® - Erlotinib | Non-small cell lung cancer (NSCLC): Tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with EGFR- negative tumours. Pancreatic cancer: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival advantage could be shown for patients with locally advanced disease. |
www.emea.europa.eu/ humandocs/Humans/ EPAR/tarceva/tarceva.htm www.cancerbackup.org.uk/ Treatments/Biologicaltherapies/ Cancergrowthinhibitors/Erlotinib |
£1,650 per month |
| Velcade® - Bortezomib | VELCADE is indicated as mono-therapy for the treatment of progressive multiple myeloma in patients who have received at least 1 prior therapy and who have already undergone or are unsuitable for bone marrow transplantation. | www.emea.europa.eu/ humandocs/Humans/ EPAR/velcade/velcade.htm www.cancerbackup.org.uk/ Treatments/Biologicaltherapies/ Cancergrowthinhibitors/Bortezomib |
£3,050 per month |
| Zevalin® - 90Y-ibritumomab Tiuxetan | The [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin´s lymphoma (NHL). Note 2 | www.emea.europa.eu/ humandocs/Humans/ EPAR/zevalin/zevalin.htm www.cancerbackup.org.uk/ Cancertype/Lymphomanon-Hodgkin/ TypesofNHL/DiffuselargeB-cell |
£10,356 per month |
| Sprycel® - Dasatinib | SPRYCEL is indicated for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate.Note 1 SPRYCEL is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. |
www.emea.europa.eu/ humandocs/Humans/ EPAR/sprycel/sprycel.htm |
£2,500 per month |
| Vectibix® - Panitumumab | Treatment of metastatic carcinoma of the colon or rectum after failure of standard chemotherapy. | www.emea.europa.eu/ humandocs/Humans/ EPAR/vectibix/vectibix.htm www.cancerbackup.org.uk/ Treatments/Biologicaltherapies/ Monoclonalantibodies/Panitumumab |
£3,000 per month |
Note 1: Approved by Scottish Medical Consortium (SMC) and are available to NHS patients in Scotland and therefore not covered in Scotland under the terms of your plan.
Note 2: www.nyrdtc.nhs.uk/docs/eva/IBRITUMOMAB.pdf
Source: http://www.nice.org.uk, http://www.emea.europa.eu, http://www.cancerbackup.org.uk and http://www.scottishmedicines.org.uk
* These are indicative costs and may vary depending on the patient´s height and weight.
Printer friendly